Doug Melton to reunite with his Semma collaborators at Vertex to develop 'curative cell therapies'
A reunion is happening at Vertex Pharmaceuticals as the biopharma pushes forward its work in type 1 diabetes with a leading biologist set to join next month.
The famed Harvard stem cell researcher Doug Melton is joining the cystic fibrosis drugmaker as the company’s first “Distinguished Vertex Fellow,” according to an internal memo that Vertex shared with Endpoints News. STAT News first reported on Melton’s move.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.